Get the latest news from Nation Next in your inbox.
A preliminary study by Coronavirus Vaccine-induced Antibody Titre (COVAT) involving healthcare workers (HCW), who have received both doses of either Covishield or Covaxin, concluded that Covishield produced more antibodies than Covaxin. However, the conclusion of the study said that both the vaccines have elicited good immune response.
The study, which is a preprint and has yet not been peer-reviewed, said that both Covishield and Covaxin elicited a good response after two doses, but seropositivity rate and median anti-spike antibody were significantly higher in Covishield.
The study stated: " Amongst the 552 HCW (325 Male, 227 Female), 456 and 96 received the first dose of Covishield and Covaxin respectively. Overall, 79.3 per cent showed seropositivity after the first dose. Responder rate and median (IQR) rise in anti-spike antibody were significantly higher in Covishield vs Covaxin recipient (86.8 vs. 43.8 per cent; 61.5 vs 6 AU/ml; both p<0.001)."
The study further stated: "This ongoing, Pan-India, Cross-sectional, Coronavirus Vaccine-induced Antibody Titre (COVAT) study is being conducted amongst HCW, with or without past history of SARS-CoV-2 infection. SARS-CoV-2 anti-spike binding antibody is being assessed quantitatively at four timepoints between 21 days or more after the first dose to 6 months after the second dose."